Stryker Co. (NYSE:SYK) is Allred Capital Management LLC’s 6th Largest Position

Allred Capital Management LLC cut its stake in Stryker Co. (NYSE:SYK) by 0.5% in the fourth quarter, Holdings Channel reports. The fund owned 18,310 shares of the medical technology company’s stock after selling 94 shares during the period. Stryker accounts for about 2.6% of Allred Capital Management LLC’s portfolio, making the stock its 6th largest holding. Allred Capital Management LLC’s holdings in Stryker were worth $6,593,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Morse Asset Management Inc grew its position in Stryker by 16.5% in the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after acquiring an additional 200 shares in the last quarter. World Investment Advisors LLC lifted its position in Stryker by 126.1% in the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after acquiring an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new position in Stryker during the 3rd quarter worth approximately $245,000. Wilmington Savings Fund Society FSB grew its position in shares of Stryker by 13.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock worth $16,183,000 after acquiring an additional 5,361 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in Stryker by 13.9% during the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock worth $6,314,000 after purchasing an additional 2,139 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on SYK shares. Citigroup reaffirmed a “buy” rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Finally, Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $423.53.

Stryker Stock Performance

NYSE:SYK opened at $346.46 on Friday. The company has a market cap of $132.24 billion, a P/E ratio of 44.65, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm’s 50 day moving average is $371.83 and its two-hundred day moving average is $373.11. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. Analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.